13 U.S. health care stocks to consider in uncertain markets

Screened US health-care stocks (>US$25bn market cap) for five-year ROIC >15%, positive 3-month earnings revisions and 10-year EBITDA volatility <15%, highlighting defensive, profitable names. Cardinal Health: +5.3% earnings revision, ROIC 22.3%, 1‑yr price return +71.9%. Zoetis: lowest 10‑yr EBITDA std 2.5%, P/E 18.0. Intuitive Surgical: earnings revision +3.2%, ROIC 21.2%, P/E 52.9. Findings suggest stable operating profiles and select momentum/valuation tradeoffs; further due diligence recommended.

Analysis

Cardinal (CAH) is the tactical winner if logistics and distributor scale continue to matter: its distribution scale allows faster pass-through of fuel and freight shocks, steeper bargaining power with PBMs, and a structural advantage if smaller regional distributors tighten working-capital lines. A drawdown risk is capital-cycle — a sharp spike in freight costs or a PBM pricing shove could compress EBITDA within a single quarter because distribution operates on thin margins and high inventory velocity.

Zoetis (ZTS) reads like a defensive cash generator with low operating volatility, making it a good hedge against macro-driven swings in human health spending; the biggest idiosyncratic catalysts are livestock disease cycles and vet visit frequency, which operate on seasonal-to-multiyear cadences and can create 6–18 month revenue inflections. Intuitive (ISRG) is exposed to procedure-volume cyclicality and to the secular race in surgical robotics; if hospitals prioritize labor-cost reduction, adoption accelerates, but increased competition and a secondary market for refurbished systems would cap recurring consumable/service revenue and compress multiples over 1–3 years.

Near-term tradeability hinges on earnings cadence and guidance revisions over the next 1–3 quarters. The consensus appears to be pricing momentum into CAH and a safety premium into ZTS while leaving ISRG’s valuation sensitive to any negative revision; a contrarian play is to monetize ISRG’s rich multiple via option structures rather than naked short equity, and to reallocate proceeds into ZTS as the low-volatility defensive leg for 12–24 months.

Key Decisions for Investors

• Long ZTS equity (12–24 month horizon): initiate a 1–2% portfolio weight on weakness (buy into a 5–10% pullback). Target 15–25% total return if stable cashflow and multiple compression tailwinds reverse; hard stop at -12% from entry to preserve capital.
• Pair trade (6–12 months): long ZTS / short ISRG 1:1 to express stability vs multiple compression. Size at 1% net exposure; expect 8–15% relative outperformance for ZTS if procedure growth disappoints. Exit or rebalance if ISRG trades down >20% or ZTS up >20%.
• Volatility monetize ISRG (3–9 months): sell a call spread (bear call) one standard deviation out to collect premium rather than naked short. Example: sell ISRG 3–6 month 1.0–1.5x OTM call, buy further OTM call to cap risk. Reward: premium income; risk: limited to width of spread.
• Tactical momentum trade on CAH (3 months): buy on confirmation of a pullback under near-term support or post-earnings dip with a 6–12% trailing stop. Size 0.5–1% portfolio; hedge logistics cost tail with short single-digit exposure to broader transport/logistics names if freight index spikes.